Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 10Active not recruiting 10Recruiting 7Terminated 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 98Gastrointestinal 61Dermatologic 58Head & Neck 54Genitourinary 48Breast 40Gynecologic 34Other solid neoplasm 26Lymphoid 22Tumor-Agnostic 12Plasma cell 9CNS 9Sarcoma 8Other hematologic neoplasm 6Myeloid 3Endocrine 2NET 1Classical hematology 1

Conditions

Neuroendocrine Tumors 1Adrenocortical Carcinoma 1

Interventions

Everolimus 10lanreotide 4Capecitabine 4pasireotide 3lutetium Lu 177 dotatate 3lenvatinib 3fosbretabulin 3Temozolomide 3Sorafenib 3Paclitaxel 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Filgrastim 3Erlotinib Hydrochloride 3Doxorubicin 3trifluridine tipiracil drug combination 2surufatinib 2pembrolizumab 2pegfilgrastim 2gallium Ga 68 dotatate 2durvalumab 2dactolisib 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Sunitinib 2Rosiglitazone 2Radiotherapy 2Panobinostat 2Mitotane 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × pembrolizumab × Endocrine × Clear all
NCT05634577 2025-06-19

A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 7 charts
Endocrine

Adrenocortical Carcinoma

NCT03190213 2021-06-22

Pembro NEC

University of Utah

Phase 2 Terminated
6 enrolled 13 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡